Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, Cook G, Engelhardt M, Delforge M, Hajek R, Schjesvold F, Gay F, Manier S, Weisel KC, Kaiser M, van de Donk NWCJ, Zamagni E, Rodriguez-Otero P, Perrot A, Driessen C, Bila J, Laane E, Dytfeld D, Touzeau C, Beksac M et al. (2025)
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Nat Rev Clin Oncol (in press)
DOI 10.1038/s41571-025-01041-x, PubMed 40624367

van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, Spencer A, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CL, Broijl A, Touzeau C, Manier S, Hajek R, Ludwig H, Fernandez de Larrea C et al. (2025)
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Lancet Haematol (in press)
DOI 10.1016/S2352-3026(25)00117-6, PubMed 40580975

Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J et al. (2025)
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
J Clin Oncol, JCO2500744 (in press)
DOI 10.1200/JCO-25-00744, PubMed 40459178